120 gene Personalizing treatment solution
 

120 gene personalizing treatment solution is a second-generation sequencing technology used to detect and tumor development and targeted therapy-related gene products. Through the detection of cancer patients with targeted drugs, signaling pathways and tumor genetic susceptibility related genes, to guide the individual patients with cancer patients and genetic risk assessment.

 
Caner Type
Solid Tumor
 
Biopsy Type
Tissue, FFPE, Peripheral Whole Blood
 
Results Expected
10 working days
Clinical significance
Indication of targeted drug efficiency

Some mutations may be driver gene mutations for multiple cancers, such as ALK gene mutations that are not only driver gene for non-small cell lung cancer, but also with lymphoma, kidney cancer, neuroblastoma, and so on. This means that different cancer with the same driver gene mutation may be treated with the same drug. By detecting the target of all targeted drugs, the specific molecular typing of the tumor can be revealed to match the precise targeted drug for treatment.

 0826120基因个体化治疗解决方案正面 - 副本.jpg

PET scan showed that after using targeted drugs, liver metastases, bone metastases of the tumor tissue was significantly reduced, pleural effusion also significantly improved.

Indication genetic risk to guide cancer early prevention

The latest study found that 2, 22 kinds of cancer are genetic related, if the immediate family members have these cancer, other brothers and sisters have the same cancer risk will increase by 33%.

 

blob.png

By detecting BRCA gene in 1816 breast cancer patients and their 5549 first-degree female relatives, it was found that people with BRCA-induced mutations had a greater risk of developing breast cancer than those who did not carry pathogenic mutations3. Tumor hereditary related genetic detection can reveal the risk of cancer, to achieve so early detection, early diagnosis and early treatment.

Detection of ctDNA mutation information to guide patients with individualized medication

After several splitting proliferation, the daughter of tumor cells showing a molecular biology or genetic changes, leading tumor growth rate, invasive ability, sensitivity to the drug, prognosis and etc., differences.  As a new tumor marker in the monitoring of the dynamic development of the tumor,ctDNA has a higher sensitivity and specificity, and can be better than the protein markers and imaging predict the dynamic development of the tumor. So ctDNA can be used for cancer early diagnosis, monitoring cancer development process, prognosis and individualized medication guidance.

 图片4.png

图片5.png

 

PPatients with high ctDNA PIK3CA mutations frequency had a shorter recurrence-free survival (P = 0.0002) and a lower overall survival (P = 0.048) than those with no mutations or low mutation frequency Multivariate analysis of OS showed that ctDNA PIK3CA mutant frequency was an independent predictor of OS.


Product Content

 

Gene List
Gene List(120)

0826120基因个体化治疗解决方案背面.jpg

 

 

Targeted drugs
CFDA/FDA approved targeted drugs (51)
  • Olaparlb
  • Trametinib
  • Vemurafenib
  • Necitumumab
  • Temsirolimus
  • Ceritinib
  • Cobimetinib
  • Ibrutinib
  • Palbociclib
  • Panitumumab
  • Erlotinib
  • Bosutinib
  • Ruxolitinib
  • Sonidegib
  • Sorafenb
  • Erlotinib
  • Cetuximab
  • Vandetanib
  • Everolimus
  • Axitinib
  • Vismodegib
  • Dabrafenib
  • Sunitinib
  • Lapatinib
  • Nimotuzumab
  • Ponatinib
  • Apatinib
  • Decitabine
  • Regorafenib
  • Dasatinib
  • Osimertinib
  • Pertuzumab
  • Pazopanib
  • Ziv-aflibercept
  • Azacitidine
  • Nintedanib
  • Imatinib
  • Gefitinib
  • Ado-trastuzumab
  • Lenvatinib
  • Ramucirumab
  • Pembrolizumab
  • Crizotinib
  • Icotinib
  • Afatinib
  • Trastuzumab
  • Cabozantinib
  • Bevacizumab
  • Nivolumab
  • Atezolizumab
  • Alectinib

 


       

Service Process
  • Identify test program and fill in the application form

  • Get tissue and blood samples

  • Sign informed consent

  • Shipping to cloudhealth clinical center

  • Sequencing and analysis

  • Report

Reference

 

1.     Loaiza-Bonilla A, et al. E cancer medical science. 2014. 8:479.

2.     Mucci LA, et al. Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. JAMA. 2016, 315(1): 68-76.

3.     Yao L, et al. Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations. Breast Cancer Res Treat. 2016 Apr;156(3):441-5.

4.    Breast Cancer Res Treat,2015,March.

 


Immediate consultation or appointment testing services
Please select
  • 受检者
  • 研究人员
  • 医生
  • 公司
  • 其他

You can dial400-158-5999 The hotline contact us, or fill in your contact information and concerns, we will contact you in time